Talk to us a little bit about what you did and what you found.

Dr. Gibson, thank you very much for interviewing me on the ACC regarding this study.

What we are actually going to show you is the two-year data of the tri-luminate study.

As you know, about two years ago in the same ACC, we had presented the one-year data between tricuspid repair versus medical therapy.

And what we found was that it met its endpoint primarily driven by quality of life improvement, but there was no difference in mortality or heart failure admissions.

Subsequent to that, there was actually an increase in randomization.

So we have a total of now 572 patients randomized one-to-one to tear versus medical therapy.

As expected, based on symptoms,